| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/17/2005 | WO2005014836A2 Chimaeric vector system |
| 02/17/2005 | WO2005014806A2 Conserved hbv and hcv sequences useful for gene silencing |
| 02/17/2005 | WO2005014796A2 Methods and compositions for seamless cloning of nucleic acid molecules |
| 02/17/2005 | WO2005014785A2 Conditionally-immortalized hematopoietic progenitor cell lines |
| 02/17/2005 | WO2005014778A2 Dna vaccine expressing ha1 of equine-2 influenza virus |
| 02/17/2005 | WO2005014775A2 Raav compositions and methods for delivery of human factor vii polypeptides and treatment of hemophilia a |
| 02/17/2005 | WO2005014645A2 Pedf-r receptor and uses |
| 02/17/2005 | WO2005014609A2 Method of producing a highly stereoregular phosphorus atom-modified nucleotide analogue |
| 02/17/2005 | WO2005014039A2 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative diseases |
| 02/17/2005 | WO2005014033A1 Use of human growth hormone in multiple system atrophy |
| 02/17/2005 | WO2005014017A1 Medicinal composition for treating cancer |
| 02/17/2005 | WO2005013918A2 Compositions, methods and kits relating to poxvirus subunit vaccines |
| 02/17/2005 | WO2005013901A2 Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| 02/17/2005 | WO2005013895A2 Compositions and methods for the treatment of schizophrenia and addictive disorders |
| 02/17/2005 | WO2005013802A2 Trefoil factor 3 (tff3) as a target for anti-cancer therapy |
| 02/17/2005 | WO2004111082A3 Compound containing polyprotein ns3/ns4 and hcv polypeptide ns5b, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof |
| 02/17/2005 | WO2004083398A3 Therapeutic uses of hmgn1 and hmgn2 |
| 02/17/2005 | WO2004081189A9 Multimodality imaging of reporter gene expression using a novel fusion vector in living cells and organisms |
| 02/17/2005 | WO2004072249A3 Polyvinylethers for delivery of polynucleotides to mammalian cells |
| 02/17/2005 | WO2004047740A3 Composition and method for treating lupus nephritis |
| 02/17/2005 | WO2004016805A3 Immunostimulatory nucleic acids |
| 02/17/2005 | WO2004014312A3 Small-mer compositions and methods of use |
| 02/17/2005 | WO2004005457A3 Tfc/ beta-catenin regulated genes for treating cancer |
| 02/17/2005 | WO2003104412A3 Spliceosome mediated rna trans-splicing and correction of factor viii genetic defects |
| 02/17/2005 | WO2003102214A3 Method for efficient rna interference in mammalian cells |
| 02/17/2005 | WO2003101396A3 Helper virus-free herpesvirus amplicon particles and uses thereof |
| 02/17/2005 | WO2003070910A3 INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/17/2005 | WO2003062373A3 Methods and materials for the recruitment of endothelial cells |
| 02/17/2005 | WO2003050258A3 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 02/17/2005 | WO2002088304A3 Compositions and methods for suppressing immune responses |
| 02/17/2005 | WO2002083714A3 Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby |
| 02/17/2005 | US20050039232 DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses |
| 02/17/2005 | US20050038499 Methods for coating stents with DNA and expression of recombinant genes from DNA coated stents in vivo |
| 02/17/2005 | US20050038239 Locked nucleic acid conjugate for use in treatment of cell proliferative disorders |
| 02/17/2005 | US20050037989 Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| 02/17/2005 | US20050037988 Determination competitive binder between Rna and target compound in plants |
| 02/17/2005 | US20050037986 p53 treatment of papillomavirus and carcinogen-transformed cells in hyperplastic lesions |
| 02/17/2005 | US20050037971 Use of hepcidin as a regulator of iron homeostasis |
| 02/17/2005 | US20050037969 Molecular interactions in hematopoietic cells |
| 02/17/2005 | US20050037966 Keratinocyte growth factor-2 |
| 02/17/2005 | US20050037965 Use of PAK inhibitor for the treatment of a joint disease |
| 02/17/2005 | US20050037961 Generation, maintenance vascular system tissue; controlling gene expression; cardiovascular disorders |
| 02/17/2005 | US20050037955 Bactericides; fungicides; isolated polypeptides; inflammatory bowel disorders; infections |
| 02/17/2005 | US20050037497 Compounds and methods to enhance rAAV transduction |
| 02/17/2005 | US20050037495 Human CNS cell lines and methods of use therefor |
| 02/17/2005 | US20050037494 Using antisense agents to reduce and/or prevention genic expression associated with cardi-vascular complications; gene therapy |
| 02/17/2005 | US20050037487 Recombinant influenza vectors with a PolII promoter and ribozymes for vaccines and gene therapy |
| 02/17/2005 | US20050037469 Fusion polypeptide comprising a collagen-binding domain and an epithelial cell proliferation-modulating domain for use as tool in regenerative medicine and tissue repair |
| 02/17/2005 | US20050037462 Expression vector comprising nucleotide sequences coding g protein for use in generating immunoglobulins for use in prevention, treatment and diagnosis of cell proliferative disorders |
| 02/17/2005 | US20050037445 analyzing molecules expressed on the cell surface of cancer cells and comparing to nonmalignant cells; screening for cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer |
| 02/17/2005 | US20050037419 Compositions and methods relating to lung specific genes and proteins |
| 02/17/2005 | US20050037404 Methods of modulating drug clearance mechanisms by altering SXR activity |
| 02/17/2005 | US20050037401 Photocleavable DNA transfer agent |
| 02/17/2005 | US20050037370 RNA-induced silencing complexes; RNA interference; gene expression inhibition |
| 02/17/2005 | US20050037345 Gene with polynucleopotide codes with polypeptide with amino acid sequences for domains and molecular hybridization for gene expression and cancer |
| 02/17/2005 | US20050037340 Immunoglobulin for use in detection of simian and lymphadenopathy associated viral infection in mammals; immunodiagnostics |
| 02/17/2005 | US20050037086 Continuous-flow method for preparing microparticles |
| 02/17/2005 | US20050037085 Microencapsulated DNA for vaccination and gene therapy |
| 02/17/2005 | US20050037075 Targeted delivery of controlled release polymer systems |
| 02/17/2005 | US20050037017 Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
| 02/17/2005 | US20050037010 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050036997 Molecular modeling of the binding sites for anisomycin, azithromycin, erythromycin, linezolid, tylosin, carbomycin A, spiramycin, virginiamycin, sparsomycin and blasticidin using the Haloarcular marismortui large ribosomal subunit; drug design and drug screening |
| 02/17/2005 | US20050036995 Immunogens; tumor antigens; kits |
| 02/17/2005 | US20050036994 Compounds and methods for downregulating the effects of TGF-beta |
| 02/17/2005 | US20050036992 Novel use of liver X receptor agonists |
| 02/17/2005 | US20050036989 Subgroup B adenoviral vectors for treating disease |
| 02/17/2005 | US20050036988 Administering vector which transduces hepatic stellate cells which suppresses collagen and/or tumor growth factor-beta expression; kits |
| 02/17/2005 | US20050036987 Suicide gene-containing strains of bacteria, fungi, and protists; tumor specific shigella species |
| 02/17/2005 | US20050036986 Antisense agents; gene expression inhibition; prostate cancer; hyperplasia; carcinoma |
| 02/17/2005 | US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/17/2005 | US20050036973 Medical polymers and uses thereof |
| 02/17/2005 | US20050036951 Methods of treating lung diseases |
| 02/17/2005 | CA2575591A1 A pharmaceutical composition for treatment of cancers |
| 02/17/2005 | CA2555323A1 Polypeptide specific to liver cancer, polynucleotide coding for the polypeptide, and rna molecule suppressing expression of the polypeptide |
| 02/17/2005 | CA2535517A1 Product comprising a c4bp core protein and a monomeric antigen, and its use |
| 02/17/2005 | CA2534909A1 P16 mediated regulation of nmda receptors |
| 02/17/2005 | CA2534899A1 Polypeptides having brain-localizing activity and uses thereof |
| 02/17/2005 | CA2534658A1 Trefoil factor 3 (tff3) as a target for anti-cancer therapy |
| 02/17/2005 | CA2532821A1 Use of human growth hormone in multiple system atrophy |
| 02/17/2005 | CA2532759A1 Active or passive immunization against proapoptotic neurotrophins for the treatment and/or prevention of neurodegenerative diseases |
| 02/17/2005 | CA2531773A1 Novel multifunctional cytokines |
| 02/17/2005 | CA2528606A1 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium |
| 02/17/2005 | CA2528510A1 Conserved hbv and hcv sequences useful for gene silencing |
| 02/17/2005 | CA2523676A1 Dna vaccine expressing ha1 of equine-2 influenza virus |
| 02/16/2005 | EP1507010A2 Control of the gene expression in eukaryotic cells |
| 02/16/2005 | EP1507005A2 Antisense modulation of BCL-X expression |
| 02/16/2005 | EP1506784A1 Identification of novel factors that block programmed cell death or apoptosis by targeting JNK |
| 02/16/2005 | EP1506409A1 Assays for modulators of asparaginyl hydroxylase |
| 02/16/2005 | EP1506318A2 Methods and compositions for regulation and manipulation of steroidogenesis |
| 02/16/2005 | EP1506317A2 Marker molecules associated with lung tumors |
| 02/16/2005 | EP1506297A2 Brachyspira hyodysenteriae vaccine |
| 02/16/2005 | EP1506232A1 Sodium channel regulators and modulators |
| 02/16/2005 | EP1506218A2 Reversible modification of membrane interaction |
| 02/16/2005 | EP1506216A2 Antisense moodulation of kinesin-like 1 expression |
| 02/16/2005 | EP1506021A2 Novel use of adenoviruses and nucleic acids coding therefor |
| 02/16/2005 | EP1506019A1 Complexes for the delivery of biologically-active material to cells |
| 02/16/2005 | EP1506010A2 Methylated immunostimulatory oligonucleotides and methods of using the same |
| 02/16/2005 | EP1505942A2 Pathogen vaccines and methods for using the same |
| 02/16/2005 | EP1296698A4 Therapeutic agents - ii |